Multaq Tablet, Film Coated
Product Images NDC 0024-4142

6 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Multaq (NDC 0024-4142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 01)

Chemical Structure (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 01)
Chemical structure of Dronedarone, the active ingredient in Multaq. The diagram shows the molecular arrangement including aromatic rings, sulfonamide, and amine groups with the hydrochloride salt form indicated.*
FDA Label Image

Figure 1 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 02)

Figure 1 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 02)
A horizontal forest plot depicting the mean ratio and 90% confidence intervals for pharmacokinetic interactions of various drugs with dronedarone. The chart compares Cmax and AUC values for antibiotics, grapefruit juice, calcium channel blockers, statins, AIIRA, and pantoprazole against dronedarone alone, showing changes in drug exposure levels on a logarithmic scale.*
FDA Label Image

Figure 2 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 03)

Figure 2 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 03)
A dot plot chart showing the mean ratio and 90% confidence intervals for pharmacokinetic parameters Cmax (red circles) and AUC (green triangles) of various interacting drugs when taken with another drug. Drugs listed include statins, digitalis, beta-blockers, calcium channel blockers, antithrombotic agents, AIIRA, and others, with doses and frequencies specified. The x-axis represents the change relative to interacting drug alone, ranging from 0.5 to 8.0.*
FDA Label Image

Figure 3 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 04)

Figure 3 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 04)
A Kaplan-Meier cumulative incidence curve comparing Placebo and Dronedarone over 30 months. The y-axis represents cumulative incidence, and the x-axis shows time in months. The graph includes a table below displaying the number of subjects at risk for both Placebo and Dronedarone groups at several time points.*
FDA Label Image

Figure 4 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 05)

Figure 4 (7fa41601 7fb5 4155 8e50 2ae903f0d2d6 05)
A forest plot chart comparing the relative risk (RR) and 95% confidence intervals for various patient characteristics, evaluating Dronedarone versus placebo effectiveness. Characteristics include age groups, gender, presence of AF/AFL, structural heart disease, NYHA class, LVEF percentage, and use of beta-blocking agents, ACE inhibitors or ARBs, digitalis, and calcium antagonists, with respective RR values and p-values shown.*
FDA Label Image

Principal Display Panel (60 Tablet Bottle)

Principal Display Panel (60 Tablet Bottle)
Label for Multaq (dronedarone) tablets, 400 mg strength, oral film-coated tablets. The label indicates a package size of 60 tablets and is manufactured by Sanofi-Aventis U.S. LLC. It includes the NDC 0024-4142-60, a barcode, and instructions to dispense with a medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.